What is GMP? TDP Explains Good Manufacturing Practice for Pharmaceutical Manufacturers
What is GMP? A practical explanation for pharmaceutical manufacturers
GMP is short for Good Manufacturing Practice. If you manufacture medicines, GMP is not optional. It is the standard regulators use to decide whether your site can manufacture, release, and supply product safely and consistently.
Most people understand that in theory. In practice, GMP becomes urgent when you are: preparing for a licence, facing an inspection, scaling production, or recovering from recurring quality issues.
This article explains GMP in plain terms; what it actually means, what inspectors look for, and where companies most often get caught out.
What does GMP mean?
GMP is the set of requirements that ensure medicines are manufactured to the right quality standard every time, not just when the site is calm, fully staffed, and running smoothly.
At its core, GMP is about control:
• you control your process (so it produces consistent output)
• you control your facility and equipment (so it doesn’t introduce risk)
• you control your people and training (so work is done correctly)
• you control your materials and suppliers (so inputs are reliable)
• you control your data and documentation (so decisions are supported by evidence)
A simple rule holds: if you can’t show evidence, you can’t claim control.
Why GMP matters (beyond “compliance”)
GMP exists to protect patients. That is the headline reason.
But for manufacturers, GMP also protects the business. Weak GMP leads to the things that cost time and money quickly: batch failures, repeat deviations, slow investigations, delayed release, audit failures, and regulatory escalation.
Strong GMP usually looks boring from the outside. That’s the point. It is stable, repeatable, and well owned.
Who enforces GMP?
In the UK, GMP inspections are carried out by the MHRA. In the US, it is the FDA. In Europe and other regulated markets, expectations align around the same fundamentals: documented systems, controlled processes, and data you can trust.
Inspection styles vary. The themes do not.
What inspectors are actually testing
Inspectors do not only check whether you have SOPs. They test whether your system works.
They typically probe five areas because these are where risk enters:
1) Quality system ownership
Are there clear ownership of deviations, CAPA, change control, complaints, supplier management, and management review? Or is everything “Quality’s problem” and nobody owns the system in day-to-day operations?
2) Deviation and investigation quality
Are deviations written clearly and raised promptly? Do investigations identify root cause, or do they default to “operator error” with retraining as the only action?
This is a common point of failure. Re-training is not a corrective action if the system allows the issue to recur.
3) Change control discipline
Is change properly assessed before implementation, process changes, supplier changes, equipment changes, procedural changes? Or do changes happen informally and get documented afterwards?
Uncontrolled change is one of the fastest ways for GMP to drift.
4) Data integrity and documentation control
Can you reconstruct what happened for a batch without gaps or guesswork? Are records attributable, legible, contemporaneous, original, and accurate? Are templates controlled and versions clear? Are audit trails understood?
If inspectors lose confidence in data, everything else becomes harder to defend.
5) Training and competence in practice
Training files matter, but inspectors often check competence by speaking to people. They want to see consistent understanding of critical steps, not just signatures on a training record.
Three common GMP weaknesses that trigger findings
Weak investigations and superficial CAPA
A deviation occurs, the write-up is thin, the root cause is vague, and the CAPA is “retrain” or “remind.” The same issue reappears. Inspectors notice recurrence quickly.
Informal change that isn’t controlled
A “small” adjustment is made because it seems low risk, then later the batch output shifts, records don’t line up, or validation no longer reflects reality.
Records that don’t stand up
Missing entries, unclear corrections, uncontrolled worksheets, or data copied into records without traceability. Even if the product is fine, the story is not defensible.
GMP for SMEs: you can be lean, but you can’t be loose
Smaller manufacturers often try to solve GMP by adding paperwork. That usually makes things worse.
The goal is not more documents. The goal is a system that is used consistently and still holds up when the site is busy.
A lean GMP system is:
• clear ownership
• simple and repeatable processes
• controlled documents and templates
• investigation and CAPA that actually prevents recurrence
• management oversight that uses trend data, not anecdotes
A practical way to think about GMP readiness
If you have an inspection, audit, or licensing milestone approaching, ask one question:
If an inspector picked any batch at random, could we clearly show what happened, why decisions were made, and how risks were controlled—without relying on “the right person” being in the room?
If the answer is uncertain, it is usually worth doing a structured readiness review before the pressure hits.
GMP Readiness Support
If you’re preparing for licensing, an MHRA inspection, or you want to reduce recurring quality issues, TDP can support with a focused GMP readiness review.
We typically assess the areas that drive inspection outcomes fastest: deviations and CAPA, change control, documentation/data integrity, training effectiveness, and quality oversight—then produce a prioritised action plan that can be implemented without creating unnecessary process burden.
Book a GMP readiness call to discuss your timeline and the quickest route to inspection confidence.
GMP Inspection Readiness FAQs
-
A GMP mock inspection is a structured, inspection-style review of your site against regulatory expectations. It tests whether your systems work in practice (not just on paper), identifies likely inspection findings, and produces a prioritised remediation plan before a real regulator or customer audit.
-
A robust gap assessment typically covers: the Quality Management System (QMS), deviations/CAPA, change control, documentation control, batch record practices, training/competence, supplier management, validation/qualification status, data integrity controls, and management oversight (trending and review). The output should be risk-ranked actions with owners and realistic timelines.
-
These are categories used in inspections to indicate severity. In simple terms: critical findings present serious risk (often patient safety or data integrity), major findings are significant compliance failures that could impact quality, and other/minor findings are issues that still require correction but are lower risk. The categories affect urgency, regulatory scrutiny, and remediation expectations.
-
An inspection is performed by a regulator and can lead to enforcement action. An audit is typically performed by customers, third parties, or internally, and is used to assess compliance and supplier/site assurance. Both assess GMP, but the authority and consequences differ.
GMP systems and validation FAQs
-
Batch record review is the formal check that manufacturing activities were performed correctly and documented properly before a batch is released. Regulators expect batch records to be complete, legible, traceable, and consistent with approved instructions, including documented deviations and approved changes.
-
Data integrity means data is trustworthy and traceable. ALCOA stands for Attributable, Legible, Contemporaneous, Original, Accurate; ALCOA+ adds expectations like Complete, Consistent, Enduring, and Available. It’s essentially a checklist for defensible records.
-
Change control is the formal GMP process used to assess, approve, implement, and document changes before they happen, so that quality risk is understood and controlled. It’s required whenever a change could impact product quality, patient safety, regulatory compliance, or data integrity.
Typical examples include changes to raw materials/suppliers, manufacturing steps or parameters, equipment, premises/layout, analytical methods, specifications, labels/packaging, SOPs and controlled documents, and computerised systems. A strong change control shows a clear risk assessment, defined actions (e.g., validation/qualification, training, stability impact), approvals, and verification that the change worked as intended. -
CAPA stands for Corrective and Preventive Action. It’s the structured way GMP sites respond to issues (deviations, complaints, audit findings, OOS) to fix the problem now and stop it coming back.
A common inspection weakness is CAPA that relies on “retrain” without changing the system that allowed the issue to occur. -
Validation is documented evidence that a process, method, piece of equipment, or system consistently performs as intended and produces results that meet predefined requirements. In GMP it’s how you demonstrate that your operation is repeatable and in control, not dependent on luck or individual experience.
Validation commonly includes process validation (manufacturing consistently meets specifications), cleaning validation (cleaning removes residues/contaminants effectively), analytical method validation (tests are reliable), equipment qualification (IQ/OQ/PQ), and computer system validation where systems affect GMP data or decisions. The aim is confidence: if you run the process again tomorrow, it should produce the same compliant outcome. -
These are qualification stages for equipment/systems:
• IQ (Installation Qualification): installed correctly per specification
• OQ (Operational Qualification): operates as intended across defined ranges
• PQ (Performance Qualification): performs consistently in routine conditions
They provide documented evidence that equipment is fit for purpose
Book a confidential call with one of our GMP Experts and discuss how TDP can help you ensure you’re inspection ready